Sellas Life Sciences shares jump as key leukemia trial results near
cocorattanakorn/iStock via Getty Images
Sellas Life Sciences Group (SLS) shares jumped 20% in extended trading Thursday after the cancer-drug developer said it expects pivotal leukemia trial results this month and reported a quarterly loss per share in line with Wall Street expectations.
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.